Adrian is a seasoned IP lawyer who relishes immersing himself in his client’s technology, product roadmap and patent/IP strategy. He is regularly involved in the negotiation and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.

Adrian has a wealth of experience in handling the IP aspects of University spin-outs, IPOs and other major corporate transactions and disputes, including for FTSE 100 and Fortune 500 corporations. He is also a valued patent litigator, having recently advised on disputes involving pharmaceuticals, somatic cell therapy, semiconductor chip design, inkjet printing technology, digital compression algorithms, LCD flat-panel technology, telecoms and pharmaceuticals. He also frequently helps clients with disputes involving confidential information, database rights, trade marks, copyright and designs.

Adrian publishes and speaks regularly on a variety of intellectual property issues.

显示完整简历 隐藏完整简历

最新新闻和观点

公司/并购与资本市场

Revolutionising access to biology with transformational acquisition by Nuclera

2021年5月13日

作者 Ross McNaughton 以及 Adrian Toutoungi

点击此处了解更多
酒店与休闲

Edison Open House Global Healthcare 2021 – key takeaways from our panel

2021年2月4日
Quick read

作者

点击此处了解更多
酒店与休闲

One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session

2021年1月6日
Quick read

作者 Adrian Toutoungi

点击此处了解更多
Pipets
专利与创新

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

2020年11月23日
Quick read

作者

点击此处了解更多

与我会面:

9月22日

16:00 - 17:00

剑桥
网络研讨会

Cell & gene therapy partnering and deal-making – where now?

Panel discussion in partnership with One Nucleus

更多